Resverlogix Corp. (TSE:RVX – Get Free Report) shares hit a new 52-week low on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 1525 shares. The stock had previously closed at C$0.05.
Resverlogix Price Performance
The stock has a market cap of C$9.90 million, a P/E ratio of -2.48 and a beta of 0.71. The company has a quick ratio of 0.04, a current ratio of 0.13 and a debt-to-equity ratio of -10.95. The business’s 50-day simple moving average is C$0.05 and its two-hundred day simple moving average is C$0.06.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- What Are Some of the Best Large-Cap Stocks to Buy?
- Energy Transfer: Powering Data With Dividends and Diversification
- How to Invest in the Best Canadian Stocks
- Qualcomm Stock Is Coiling for a Breakout
- Best Stocks Under $5.00
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
